Identifying the earliest events in HIV-1 associated nephropathy via genome-wide
通过全基因组识别 HIV-1 相关肾病的最早事件
基本信息
- 批准号:8234176
- 负责人:
- 金额:$ 33.07万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2010
- 资助国家:美国
- 起止时间:2010-05-01 至 2015-02-28
- 项目状态:已结题
- 来源:
- 关键词:AfricanAllelesBiopsyCell LineChromosomes, Human, Pair 3ClinicalComplexComplicationCongenic MiceCongenic StrainDataDevelopmentDiseaseDisease ProgressionDissectionEarly identificationEpithelial CellsEventExhibitsFiltrationGene ExpressionGene Expression ProfileGene Expression ProfilingGenerationsGenesGeneticGenetic Predisposition to DiseaseGenetic VariationGenotypeGoalsHIV-1HumanHuman GeneticsIndividualInfectionInjuryKidneyKidney DiseasesKidney FailureLesionLinkMapsMediatingMediator of activation proteinMolecularMusMyosin Heavy ChainsNPHS2 proteinNamesPathogenesisPathologicPathway interactionsPatternPhenotypePredispositionProcessProteinsRoleStructureSusceptibility GeneTestingTherapeutic InterventionTransgenic MiceTransgenic OrganismsValidationbasecandidate validationclinical phenotypecohortcomparativegene discoverygenetic linkage analysisgenome-widein vivoinsightmolecular phenotypemouse modelnephrinnon-muscle myosinnovelpodocyteprogramspublic health relevancestressor
项目摘要
DESCRIPTION (provided by applicant): The goals of this project are to use a validated mouse model to dissect molecular pathways mediating he development of HIV-1 associated nephropathy (HIVAN). HIVAN is a major complication of HIV-1 infection with distinct pathologic features. This disorder is caused by HIV-1 induced dedifferentiation of glomerular podocytes, the terminally differentiated epithelial cells that maintain the structure of the kidney filtration barrier. Genetic susceptibility to HIVAN has complex determination, with significant contribution from genetic variation in the nonmuscle myosin heavy chain 9 (MYH9), a podocyte expressed gene. HIV-1 transgenic mice on the FVB/NJ genetic background recapitulate all the clinical and pathologic hallmarks of HIVAN. Using mapping cohorts between mice with contrasting susceptibility to HIVAN, we have identified three nephropathy susceptibility loci that map to chromosomes 3, 13, 4 respectively (named HIVAN1- 3) and have confirmed mapping data by examination of congenic mice that capture these intervals. By combining linkage analysis with gene expression profiling (eQTL mapping) in F2 segregants, we have also demonstrated that the murine HIVAN susceptibility loci encode transregulators of podocyte gene expression and belong to the same pathway as known human nephropathy genes (Myh9, Podocin, Nephrin, Cd2ap). The introduction of HIV-1 results in significant perturbations of the relationship between genotype and expression of specific sets of podocyte genes, indicating that HIV-1 interferes with transregulation. These considerations indicate that careful dissection of clinical and molecular phenotypes associated with each HIVAN locus and identifications of genes that demonstrate the greatest perturbation in transregulation upon HIV-1 exposure can elucidate the earliest events in the initiation of nephropathy and delineate dysregulated molecular networks mediating disease pathogenesis. To achieve these aims, we will first perform phenotypic characterization of HIVAN congenic mice to identify the contribution of each locus to initiation and progression of disease. Next we will perform analysis of glomerular transcriptome in HIV-1 transgenic congenic mice and wiltype counterparts to infer the glomerular interactome in HIVAN and discover genes that demonstrate aberrant patterns of transregulations. Finally, these genes will be validated by eQTL mapping in HIVAN segregants, by functional studies in human podocytes and ultimately, by generation of transgenic lines that will confirm findings. Identification of molecular mediators of HIVAN is expected to provide significant insight into the pathogenesis of disease and provide novel targets for therapeutic intervention.
PUBLIC HEALTH RELEVANCE: HIV-1 associated nephropathy is a major complication of HV-1 infection and a significant cause of kidney failure worldwide. Identification of molecular mediators of HIVAN is expected to provide significant insight into the pathogenesis of disease and provide novel targets for therapeutic intervention.
描述(由申请人提供):本项目的目标是使用经验证的小鼠模型来剖析介导HIV-1相关肾病(HIVAN)发生的分子途径。HIVAN是HIV-1感染的主要并发症,具有独特的病理特征。这种疾病是由HIV-1诱导的肾小球足细胞的去分化引起的,肾小球足细胞是维持肾脏过滤屏障结构的终末分化的上皮细胞。HIVAN的遗传易感性具有复杂的决定因素,非肌肉肌球蛋白重链9(MYH 9)(足细胞表达基因)的遗传变异起着重要作用。FVB/NJ遗传背景的HIV-1转基因小鼠概括了HIVAN的所有临床和病理特征。使用对HIVAN具有不同易感性的小鼠之间的映射队列,我们已经确定了分别映射到染色体3、13、4的三个肾病易感性位点(命名为HIVAN 1 - 3),并且通过检查捕获这些间隔的同类小鼠确认了映射数据。通过将连锁分析与F2分离体中的基因表达谱(eQTL作图)相结合,我们还证明了小鼠HIVAN易感基因座编码足细胞基因表达的反式调节子,并且与已知的人类肾病基因(Myh 9、Podocin、Nephrin、Cd 2ap)属于相同的途径。HIV-1的引入导致足细胞基因的基因型和特定组的表达之间的关系的显着扰动,表明HIV-1干扰反式调节。这些考虑表明,仔细解剖与每个HIVAN位点相关的临床和分子表型,并鉴定在HIV-1暴露后反式调节中表现出最大扰动的基因,可以阐明肾病发生的最早期事件,并描绘介导疾病发病机制的失调分子网络。为了实现这些目标,我们将首先进行HIVAN同源小鼠的表型表征,以确定每个位点对疾病发生和进展的贡献。接下来,我们将在HIV-1转基因同源小鼠和野生型小鼠中进行肾小球转录组分析,以推断HIVAN中的肾小球相互作用组,并发现表现出异常转录模式的基因。最后,这些基因将通过在HIVAN分离子中进行eQTL定位、通过在人足细胞中进行功能研究以及最终通过产生将证实发现的转基因系来验证。HIVAN分子介质的鉴定有望为疾病的发病机制提供重要的见解,并为治疗干预提供新的靶点。
公共卫生相关性:HIV-1相关肾病是HV-1感染的主要并发症,也是全球肾衰竭的重要原因。HIVAN分子介质的鉴定有望为疾病的发病机制提供重要的见解,并为治疗干预提供新的靶点。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
ALI G GHARAVI其他文献
ALI G GHARAVI的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('ALI G GHARAVI', 18)}}的其他基金
Columbia/Cornell/Harlem Hospital Precision Medicine Initiative HPO
哥伦比亚/康奈尔/哈莱姆医院精准医学计划 HPO
- 批准号:
9525197 - 财政年份:2016
- 资助金额:
$ 33.07万 - 项目类别:
Columbia/Cornell/Harlem Hospital Precision Medicine Initiative HPO
哥伦比亚/康奈尔/哈莱姆医院精准医学计划 HPO
- 批准号:
9228787 - 财政年份:2016
- 资助金额:
$ 33.07万 - 项目类别:
Columbia GENIE (GENomic Integration with Ehr)
Columbia GENIE(基因组与 Ehr 集成)
- 批准号:
9134799 - 财政年份:2015
- 资助金额:
$ 33.07万 - 项目类别:
Columbia GENIE (GENomic Integration with Ehr)
Columbia GENIE(基因组与 Ehr 集成)
- 批准号:
9896294 - 财政年份:2015
- 资助金额:
$ 33.07万 - 项目类别:
Columbia GENIE (GENomic Integration with Ehr)
Columbia GENIE(基因组与 Ehr 集成)
- 批准号:
8968053 - 财政年份:2015
- 资助金额:
$ 33.07万 - 项目类别:
Human genetic approaches to lower urinary tract phenotypes
降低尿路表型的人类遗传学方法
- 批准号:
10297545 - 财政年份:2014
- 资助金额:
$ 33.07万 - 项目类别:
The Host Genome and the Urinary Microbiome in UTI and GU Structural Defects
UTI 和 GU 结构缺陷中的宿主基因组和泌尿微生物组
- 批准号:
10022308 - 财政年份:2014
- 资助金额:
$ 33.07万 - 项目类别:
Human genetic approaches to lower urinary tract phenotypes
降低尿路表型的人类遗传学方法
- 批准号:
10700954 - 财政年份:2014
- 资助金额:
$ 33.07万 - 项目类别:
Human genetic approaches to lower urinary tract phenotypes
降低尿路表型的人类遗传学方法
- 批准号:
10487492 - 财政年份:2014
- 资助金额:
$ 33.07万 - 项目类别:
The Columbia PCC for CureGN: the Cure Glomerulonephropathy network
哥伦比亚 PCC for CureGN:治愈肾小球肾病网络
- 批准号:
10212101 - 财政年份:2013
- 资助金额:
$ 33.07万 - 项目类别:
相似海外基金
Linkage of HIV amino acid variants to protective host alleles at CHD1L and HLA class I loci in an African population
非洲人群中 HIV 氨基酸变异与 CHD1L 和 HLA I 类基因座的保护性宿主等位基因的关联
- 批准号:
502556 - 财政年份:2024
- 资助金额:
$ 33.07万 - 项目类别:
Olfactory Epithelium Responses to Human APOE Alleles
嗅觉上皮对人类 APOE 等位基因的反应
- 批准号:
10659303 - 财政年份:2023
- 资助金额:
$ 33.07万 - 项目类别:
Deeply analyzing MHC class I-restricted peptide presentation mechanistics across alleles, pathways, and disease coupled with TCR discovery/characterization
深入分析跨等位基因、通路和疾病的 MHC I 类限制性肽呈递机制以及 TCR 发现/表征
- 批准号:
10674405 - 财政年份:2023
- 资助金额:
$ 33.07万 - 项目类别:
An off-the-shelf tumor cell vaccine with HLA-matching alleles for the personalized treatment of advanced solid tumors
具有 HLA 匹配等位基因的现成肿瘤细胞疫苗,用于晚期实体瘤的个性化治疗
- 批准号:
10758772 - 财政年份:2023
- 资助金额:
$ 33.07万 - 项目类别:
Identifying genetic variants that modify the effect size of ApoE alleles on late-onset Alzheimer's disease risk
识别改变 ApoE 等位基因对迟发性阿尔茨海默病风险影响大小的遗传变异
- 批准号:
10676499 - 财政年份:2023
- 资助金额:
$ 33.07万 - 项目类别:
New statistical approaches to mapping the functional impact of HLA alleles in multimodal complex disease datasets
绘制多模式复杂疾病数据集中 HLA 等位基因功能影响的新统计方法
- 批准号:
2748611 - 财政年份:2022
- 资助金额:
$ 33.07万 - 项目类别:
Studentship
Genome and epigenome editing of induced pluripotent stem cells for investigating osteoarthritis risk alleles
诱导多能干细胞的基因组和表观基因组编辑用于研究骨关节炎风险等位基因
- 批准号:
10532032 - 财政年份:2022
- 资助金额:
$ 33.07万 - 项目类别:
Recessive lethal alleles linked to seed abortion and their effect on fruit development in blueberries
与种子败育相关的隐性致死等位基因及其对蓝莓果实发育的影响
- 批准号:
22K05630 - 财政年份:2022
- 资助金额:
$ 33.07万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Investigating the Effect of APOE Alleles on Neuro-Immunity of Human Brain Borders in Normal Aging and Alzheimer's Disease Using Single-Cell Multi-Omics and In Vitro Organoids
使用单细胞多组学和体外类器官研究 APOE 等位基因对正常衰老和阿尔茨海默病中人脑边界神经免疫的影响
- 批准号:
10525070 - 财政年份:2022
- 资助金额:
$ 33.07万 - 项目类别:
Leveraging the Evolutionary History to Improve Identification of Trait-Associated Alleles and Risk Stratification Models in Native Hawaiians
利用进化历史来改进夏威夷原住民性状相关等位基因的识别和风险分层模型
- 批准号:
10689017 - 财政年份:2022
- 资助金额:
$ 33.07万 - 项目类别: